SUPPLEMENTARY DATA Exenatide: The Investigator’s brochure from Eli Lilly and Company (http: www.accessdata.fda.gov drugsatfda_docs label 2009 021773s9s11s18s22s25lbl.pdf) indicates that the ‘mean apparent clearance - Investigator's brochure - Document - PDFSEARCH.IO

First Page	Meta Content
	SUPPLEMENTARY DATA Exenatide: The Investigator’s brochure from Eli Lilly and Company (http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf) indicates that the ‘mean apparent clearance Add to Reading List Document Date: 2014-06-20 11:12:30 Open Document File Size: 649,96 KB Share Result on Facebook Company Merck / Eli Lilly and Company / / MedicalCondition diabetes / / Organization American Diabetes Association / / Person Glimepiride / Exenatide / Sitagliptin / / Position Investigator / / Product glucagon / Glimepiride / / Technology pharmacokinetics / / URL http / SocialTag Gastroenterology Exenatide Sitagliptin Glucagon-like peptide-1 Glimepiride Dipeptidyl peptidase-4 inhibitor Glucose tolerance test Anti-diabetic drugs Endocrine system Chemistry

SUPPLEMENTARY DATA Exenatide: The Investigator’s brochure from Eli Lilly and Company (http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf) indicates that the ‘mean apparent clearance Add to Reading List